Troubled drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the combined companies. Post-merger, the company will be listed on the New York Stock Exchange and is projected to generate around $3.6 billion in revenue this year.
Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...
Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can ...
In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback